{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:58:39Z","timestamp":1792166319419,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["TA\/2015\/035"],"award-info":[{"award-number":["TA\/2015\/035"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["STaR\/0025\/2015"],"award-info":[{"award-number":["STaR\/0025\/2015"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00262-022-03158-9","type":"journal-article","created":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T15:41:05Z","timestamp":1643557265000},"page":"2277-2286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Phase I study of expanded natural killer cells in combination with cetuximab for recurrent\/metastatic nasopharyngeal carcinoma"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9528-4365","authenticated-orcid":false,"given":"Chwee Ming","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang Piu","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lip Kun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok Seng","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt Fredrik","family":"Petersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Cher","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Shimasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,30]]},"reference":[{"issue":"5","key":"3158_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359\u2013E386. https:\/\/doi.org\/10.1002\/ijc.29210","journal-title":"Int J Cancer"},{"issue":"5","key":"3158_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126108","volume":"10","author":"H Mak","year":"2015","unstructured":"Mak H, Lee S, Chee J et al (2015) Clinical Outcome among Nasopharyngeal Cancer Patients in a Multi-Ethnic Society in Singapore. PLoS ONE 10(5):e0126108. https:\/\/doi.org\/10.1371\/journal.pone.0126108","journal-title":"PLoS ONE"},{"issue":"9","key":"3158_CR3","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jamaoncol.2020.1793","volume":"6","author":"N Riaz","year":"2020","unstructured":"Riaz N, Sherman E, Lee N (2020) The Importance of Locoregional Therapy in Metastatic Nasopharyngeal Cancer. JAMA Oncol 6(9):1353\u20131354. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1793","journal-title":"JAMA Oncol"},{"issue":"14","key":"3158_CR4","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/jco.2017.77.0388","volume":"36","author":"B Ma","year":"2018","unstructured":"Ma B, Lim W, Goh B et al (2018) Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol 36(14):1412\u20131418. https:\/\/doi.org\/10.1200\/jco.2017.77.0388","journal-title":"J Clin Oncol"},{"issue":"10192","key":"3158_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/s0140-6736(19)30956-0","volume":"394","author":"Y Chen","year":"2019","unstructured":"Chen Y, Chan A, Le Q, Blanchard P, Sun Y, Ma J (2019) Nasopharyngeal carcinoma. The Lancet 394(10192):64\u201380. https:\/\/doi.org\/10.1016\/s0140-6736(19)30956-0","journal-title":"The Lancet"},{"issue":"1","key":"3158_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/cncr.32517","volume":"126","author":"I Argirion","year":"2020","unstructured":"Argirion I, Zarins K, Ruterbusch J et al (2020) Increasing incidence of Epstein-Barr virus\u2013related nasopharyngeal carcinoma in the United States. Cancer 126(1):121\u2013130. https:\/\/doi.org\/10.1002\/cncr.32517","journal-title":"Cancer"},{"issue":"10054","key":"3158_CR7","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/s0140-6736(16)31388-5","volume":"388","author":"L Zhang","year":"2016","unstructured":"Zhang L, Huang Y, Hong S et al (2016) Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. The Lancet 388(10054):1883\u20131892. https:\/\/doi.org\/10.1016\/s0140-6736(16)31388-5","journal-title":"The Lancet"},{"issue":"7","key":"3158_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/jnci\/djz044","volume":"111","author":"Q Le","year":"2019","unstructured":"Le Q, Colevas A, O\u2019Sullivan B et al (2019) Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. J Natl Cancer Inst 111(7):655\u2013663. https:\/\/doi.org\/10.1093\/jnci\/djz044","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"3158_CR9","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/hed.24993","volume":"40","author":"Y Leong","year":"2018","unstructured":"Leong Y, Soon Y, Lee K, Wong L, Tham I, Ho F (2018) Long-term outcomes after reirradiation in nasopharyngeal carcinoma with intensity-modulated radiotherapy: a meta-analysis. Head Neck 40(3):622\u2013631. https:\/\/doi.org\/10.1002\/hed.24993","journal-title":"Head Neck"},{"key":"3158_CR10","doi-asserted-by":"publisher","unstructured":"Schwartz L, Liti\u00e8re S, de Vries E et al (2016) RECIST 1.1\u2014Update and clarification: From the RECIST committee. Eur J Cancer 62:132\u2013137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081","DOI":"10.1016\/j.ejca.2016.03.081"},{"issue":"1","key":"3158_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrclinonc.2014.192","volume":"12","author":"H Kang","year":"2015","unstructured":"Kang H, Kiess A, Chung C (2015) Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol 12(1):11\u201326. https:\/\/doi.org\/10.1038\/nrclinonc.2014.192","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"3158_CR12","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/hed.10307","volume":"25","author":"B Ma","year":"2003","unstructured":"Ma B, Poon T, To K et al (2003) Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma?a prospective study. Head Neck 25(10):864\u2013872. https:\/\/doi.org\/10.1002\/hed.10307","journal-title":"Head Neck"},{"key":"3158_CR13","doi-asserted-by":"publisher","unstructured":"Chua D, Nicholls J, Sham J, Au G (2004) Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol*Biol*Phys 59(1):11\u201320. https:\/\/doi.org\/10.1016\/j.ijrobp.2003.10.038","DOI":"10.1016\/j.ijrobp.2003.10.038"},{"issue":"9","key":"3158_CR14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nbt1137","volume":"23","author":"G Adams","year":"2005","unstructured":"Adams G, Weiner L (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23(9):1147\u20131157. https:\/\/doi.org\/10.1038\/nbt1137","journal-title":"Nat Biotechnol"},{"issue":"4","key":"3158_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrc3236","volume":"12","author":"A Scott","year":"2012","unstructured":"Scott A, Wolchok J, Old L (2012) Antibody therapy of cancer. Nat Rev Cancer 12(4):278\u2013287. https:\/\/doi.org\/10.1038\/nrc3236","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"3158_CR16","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3390\/cancers13020312","volume":"13","author":"K Dixon","year":"2021","unstructured":"Dixon K, Wu J, Walcheck B (2021) Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells. Cancers (Basel) 13(2):312. https:\/\/doi.org\/10.3390\/cancers13020312","journal-title":"Cancers (Basel)"},{"issue":"28","key":"3158_CR17","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1200\/jco.2009.27.6360","volume":"28","author":"R Ferris","year":"2010","unstructured":"Ferris R, Jaffee E, Ferrone S (2010) Tumor Antigen-Targeted, Monoclonal Antibody-Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape. J Clin Oncol 28(28):4390\u20134399. https:\/\/doi.org\/10.1200\/jco.2009.27.6360","journal-title":"J Clin Oncol"},{"issue":"20","key":"3158_CR18","first-page":"5813","volume":"62","author":"K Kono","year":"2002","unstructured":"Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y (2002) Impaired Antibody-dependent Cellular Cytotoxicity Mediated by Herceptin in Patients with Gastric Cancer. Cancer Res 62(20):5813\u20135817","journal-title":"Cancer Res"},{"issue":"1","key":"3158_CR19","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","volume":"106","author":"C Imai","year":"2005","unstructured":"Imai C, Iwamoto S, Campana D (2005) Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106(1):376\u2013383. https:\/\/doi.org\/10.1182\/blood-2004-12-4797","journal-title":"Blood"},{"issue":"9","key":"3158_CR20","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1158\/0008-5472.can-08-3712","volume":"69","author":"H Fujisaki","year":"2009","unstructured":"Fujisaki H, Kakuda H, Shimasaki N et al (2009) Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 69(9):4010\u20134017. https:\/\/doi.org\/10.1158\/0008-5472.can-08-3712","journal-title":"Cancer Res"},{"issue":"6","key":"3158_CR21","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/ijc.28780","volume":"135","author":"K Mimura","year":"2014","unstructured":"Mimura K, Kamiya T, Shiraishi K et al (2014) Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer. Int J Cancer 135(6):1390\u20131398. https:\/\/doi.org\/10.1002\/ijc.28780","journal-title":"Int J Cancer"},{"issue":"11","key":"3158_CR22","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.jcyt.2016.06.013","volume":"18","author":"N Shimasaki","year":"2016","unstructured":"Shimasaki N, Coustan-Smith E, Kamiya T, Campana D (2016) Expanded and armed natural killer cells for cancer treatment. Cytotherapy 18(11):1422\u20131434. https:\/\/doi.org\/10.1016\/j.jcyt.2016.06.013","journal-title":"Cytotherapy"},{"issue":"17","key":"3158_CR23","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1158\/1078-0432.ccr-20-0768","volume":"26","author":"S Lee","year":"2020","unstructured":"Lee S, Shimasaki N, Lim J et al (2020) Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers. Clin Cancer Res 26(17):4494\u20134502. https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-0768","journal-title":"Clin Cancer Res"},{"key":"3158_CR24","doi-asserted-by":"publisher","unstructured":"Shimasaki N, Campana D (2020) Engineering of natural killer cells for clinical application. Methods Mol Biol 2020:91\u2013105. https:\/\/doi.org\/10.1007\/978-1-0716-0203-4_6","DOI":"10.1007\/978-1-0716-0203-4_6"},{"issue":"3","key":"3158_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D (2020) NK cells for cancer immunotherapy. Nat Rev Drug Discovery 19(3):200\u2013218. https:\/\/doi.org\/10.1038\/s41573-019-0052-1","journal-title":"Nat Rev Drug Discovery"},{"key":"3158_CR26","doi-asserted-by":"publisher","unstructured":"Koene H, Kleijer M, Algra J, Roos D, E.G.Kr. von dem Borne A, de Haas M (1997) Fc\u03b3RIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc\u03b3RIIIa, independently of the Fc\u03b3RIIIa-48L\/R\/H phenotype. Blood 90(3):1109\u20131114. https:\/\/doi.org\/10.1182\/blood.v90.3.1109","DOI":"10.1182\/blood.v90.3.1109"},{"issue":"7","key":"3158_CR27","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00262-008-0613-3","volume":"58","author":"R Taylor","year":"2009","unstructured":"Taylor R, Chan S, Wood A et al (2009) Fc\u03b3RIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 58(7):997\u20131006. https:\/\/doi.org\/10.1007\/s00262-008-0613-3","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3158_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/cad.0000000000000294","volume":"27","author":"T Xu","year":"2016","unstructured":"Xu T, Ou X, Shen C, Hu C (2016) Cetuximab in combination with chemoradiotherapy in the treatment of recurrent and\/or metastatic nasopharyngeal carcinoma. Anticancer Drugs 27(1):66\u201370. https:\/\/doi.org\/10.1097\/cad.0000000000000294","journal-title":"Anticancer Drugs"},{"issue":"15","key":"3158_CR29","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1200\/jco.2005.02.147","volume":"23","author":"A Chan","year":"2005","unstructured":"Chan A, Hsu M, Goh B et al (2005) Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma. J Clin Oncol 23(15):3568\u20133576. https:\/\/doi.org\/10.1200\/jco.2005.02.147","journal-title":"J Clin Oncol"},{"key":"3158_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.oraloncology.2018.07.011","volume":"84","author":"A Lee","year":"2018","unstructured":"Lee A, Tan L, Lim C (2018) Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer. Oral Oncol 84:61\u201370. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.07.011","journal-title":"Oral Oncol"},{"issue":"14","key":"3158_CR31","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1002\/cncr.30541","volume":"123","author":"J Huang","year":"2017","unstructured":"Huang J, Fogg M, Wirth L et al (2017) Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer 123(14):2642\u20132650. https:\/\/doi.org\/10.1002\/cncr.30541","journal-title":"Cancer"},{"issue":"1","key":"3158_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/mt.2013.242","volume":"22","author":"W Chia","year":"2014","unstructured":"Chia W, Teo M, Wang W et al (2014) Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma. Mol Ther 22(1):132\u2013139. https:\/\/doi.org\/10.1038\/mt.2013.242","journal-title":"Mol Ther"},{"issue":"9","key":"3158_CR33","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/cji.0b013e3181f3cbf4","volume":"33","author":"C Louis","year":"2010","unstructured":"Louis C, Straathof K, Bollard C et al (2010) Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 33(9):983\u2013990. https:\/\/doi.org\/10.1097\/cji.0b013e3181f3cbf4","journal-title":"J Immunother"},{"issue":"1","key":"3158_CR34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/annonc\/mdh027","volume":"15","author":"P Comoli","year":"2004","unstructured":"Comoli P, De Palma R, Siena S et al (2004) Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boostsLMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol 15(1):113\u2013117. https:\/\/doi.org\/10.1093\/annonc\/mdh027","journal-title":"Ann Oncol"},{"issue":"2","key":"3158_CR35","doi-asserted-by":"publisher","DOI":"10.4161\/23723556.2014.976507","volume":"4","author":"J Li","year":"2015","unstructured":"Li J, Chen Q, He J et al (2015) Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Oncoimmunology 4(2):e976507. https:\/\/doi.org\/10.4161\/23723556.2014.976507","journal-title":"Oncoimmunology"},{"issue":"3","key":"3158_CR36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1158\/2326-6066.cir-18-0572","volume":"7","author":"R Parihar","year":"2019","unstructured":"Parihar R, Rivas C, Huynh M et al (2019) NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunol Res 7(3):363\u2013375. https:\/\/doi.org\/10.1158\/2326-6066.cir-18-0572","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"3158_CR37","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/nejmoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P et al (2020) Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 382(6):545\u2013553. https:\/\/doi.org\/10.1056\/nejmoa1910607","journal-title":"N Engl J Med"},{"issue":"6","key":"3158_CR38","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1158\/0008-5472.can-12-3558","volume":"73","author":"Y Chang","year":"2013","unstructured":"Chang Y, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D (2013) A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res 73(6):1777\u20131786. https:\/\/doi.org\/10.1158\/0008-5472.can-12-3558","journal-title":"Cancer Res"},{"issue":"7","key":"3158_CR39","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood-2014-02-556837","volume":"124","author":"M Imamura","year":"2014","unstructured":"Imamura M, Shook D, Kamiya T et al (2014) Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood 124(7):1081\u20131088. https:\/\/doi.org\/10.1182\/blood-2014-02-556837","journal-title":"Blood"},{"issue":"5","key":"3158_CR40","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1172\/jci123955","volume":"129","author":"T Kamiya","year":"2019","unstructured":"Kamiya T, Seow S, Wong D, Robinson M, Campana D (2019) Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Investig 129(5):2094\u20132106. https:\/\/doi.org\/10.1172\/jci123955","journal-title":"J Clin Investig"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03158-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03158-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03158-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T07:04:54Z","timestamp":1660287894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03158-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,30]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["3158"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03158-9","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,30]]},"assertion":[{"value":"13 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D Campana: Royalties\u2014Juno Therapeutics; stockholder and consultant\u2014Unum Therapeutics, Nkarta Therapeutics, Medisix Therapeutics; Co-inventor in patent applications for technologies relevant to study. N Shimasaki: Co-inventor in patent applications for technologies relevant to study. All remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Singapore Health Science Authority and the Institutional Review Board of the National Healthcare Group Domain Specific Review Board, Singapore (2014\/01320). All procedures were done in accordance with the Declaration of Helsinki and the ethical principles in the Belmont Report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Informed written consent was obtained prior to the patients\u2019 inclusion in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written consent was obtained from the patient depicted in Fig.\u00a0\n                      \n                      to allow the use of his picture for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}